Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2017-003838-88
    Sponsor's Protocol Code Number:M13-494
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2021-06-14
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2017-003838-88
    A.3Full title of the trial
    A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple Myeloma
    Studio Clinico Multicentrico di Fase 3, Randomizzato ed In Aperto per Valutare Venetoclax e Desametasone Rispetto a Pomalidomide e Desametasone in Soggetti con Mieloma Multiplo Recidivante o Refrattario Positivo per t(11;14)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Phase 3 Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple Myeloma
    Studio Clinico di Fase 3, per Valutare Venetoclax e Desametasone Rispetto a Pomalidomide e Desametasone in Soggetti con Mieloma Multiplo Recidivante o Refrattario Positivo per t(11;14)
    A.3.2Name or abbreviated title of the trial where available
    na
    na
    A.4.1Sponsor's protocol code numberM13-494
    A.5.4Other Identifiers
    Name:naNumber:na
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorABBVIE DEUTSCHLAND GMBH & CO. KG
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAbbVie Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAbbVie Ltd.
    B.5.2Functional name of contact pointEU Clinical Trials Helpdesk
    B.5.3 Address:
    B.5.3.1Street AddressAbbVie House, Vanwall Business Park, Vanwall Road
    B.5.3.2Town/ cityMaidenhead, Berkshire
    B.5.3.3Post codeSL6 4UB
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number441628561090
    B.5.5Fax number441628461153
    B.5.6E-maileu-clinical-trials@abbvie.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/16/1767
    D.3 Description of the IMP
    D.3.1Product nameVenetoclax
    D.3.2Product code [ABT-199 (GDC-0199)]
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNVenetoclax
    D.3.9.2Current sponsor codeABT-199 (GDC-0199)
    D.3.9.4EV Substance CodeSUB176260
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Imnovid
    D.2.1.1.2Name of the Marketing Authorisation holderCelgene Europe Ltd.
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/09/672
    D.3 Description of the IMP
    D.3.1Product nameImnovid
    D.3.2Product code [pomalidomide]
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNpomalidomide
    D.3.9.1CAS number 19171-19-8
    D.3.9.2Current sponsor codena
    D.3.9.3Other descriptive namePOMALIDOMIDE
    D.3.9.4EV Substance CodeSUB33379
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Imnovid
    D.2.1.1.2Name of the Marketing Authorisation holderCelgene Europe Ltd.
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/09/672
    D.3 Description of the IMP
    D.3.1Product nameImnovid
    D.3.2Product code [pomalidomide]
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNpomalidomide
    D.3.9.1CAS number 19171-19-8
    D.3.9.2Current sponsor codena
    D.3.9.4EV Substance CodeSUB33379
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number3
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Imnovid
    D.2.1.1.2Name of the Marketing Authorisation holderCelgene Europe Ltd.
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/09/672
    D.3 Description of the IMP
    D.3.1Product nameImnovid
    D.3.2Product code [pomalidomide]
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNpomalidomide
    D.3.9.1CAS number 19171-19-8
    D.3.9.2Current sponsor codena
    D.3.9.4EV Substance CodeSUB33379
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number4
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.1.1.1Trade name Imnovid
    D.2.1.1.2Name of the Marketing Authorisation holderCelgene Europe Ltd.
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/09/672
    D.3 Description of the IMP
    D.3.1Product nameImnovid
    D.3.2Product code [pomalidomide]
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNpomalidomide
    D.3.9.1CAS number 19171-19-8
    D.3.9.2Current sponsor codena
    D.3.9.4EV Substance CodeSUB33379
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    R/R Multiple Myeloma
    Mieloma Multiplo Recidivante o Refrattario Positivo
    E.1.1.1Medical condition in easily understood language
    Subjects with a type of blood cancer (multiple myeloma) that is either relapsed (comes back) or refractory (did not get better) after prior treatment.
    Soggetti con un tipo di tumore del sangue (mieloma multiplo) che è recidivato (ritorna) o refrattario (non migliora) dopo un precedente trattamento.
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.0
    E.1.2Level LLT
    E.1.2Classification code 10028228
    E.1.2Term Multiple myeloma
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    - To compare progression-free survival (PFS) in subjects with t(11;14)-positive MM treated with venetoclax in combination with dexamethasone versus pomalidomide in combination with dexamethasone.
    Confrontare la sopravvivenza libera da progressione (progression-free survival, PFS) nei soggetti affetti da mieloma multiplo positivo per t(11;14) trattati con venetoclax in combinazione con desametasone rispetto a pomalidomide in combinazione con desametasone.
    E.2.2Secondary objectives of the trial
    - To compare, between treatment arms (where applicable), the following:
    ¿ rate of very good partial response (VGPR) or better;
    ¿ overall response rate (ORR);
    ¿ patient reported outcomes (PRO) including Fatigue (Patient Reported Outcomes Measurement Information System [PROMIS] Fatigue Short Form 7a), Worst Pain (Brief Pain Inventory – Short Form [BPI-SF]), Physical Functioning (EORTC QLQ-C30), and Global Health Status/Quality of Life (EORTC QLQ-C30);
    ¿ overall survival (OS);
    ¿ duration of response (DOR);
    ¿ time to disease progression (TTP);
    ¿ time to response (TTR);
    ¿ minimal residual disease (MRD) negativity rate;
    ¿ pharmacokinetics of venetoclax,
    ¿ safety
    Confrontare fra bracci di trattamento (ove applicabile), i seguenti parametri:
    • Tasso di risposta pari o superiore alla risposta parziale molto buona (very good partial response, VGPR)
    • Tasso di risposta globale (overall response rate, ORR)
    • Esiti segnalati dai pazienti: Faticabilità (Patient Reported Outcomes Measurement Information System [PROMIS] Fatigue Short Form 7a), Peggior grado di dolore (Brief Pain Inventory – Short Form [BPI-SF]), Funzione fisica (EORTC QLQ-C30) e Stato di Salute Globale/Qualità di Vita (EORTC QLQ-C30)
    • Sopravvivenza globale (overall survival, OS)
    • Durata della risposta (duration of response, DOR)
    • Tempo alla progressione della malattia (time to disease progression, TTP)
    • Tempo alla risposta (time to response, TTR)
    • Tasso di negatività della malattia residua minima (minimal residual disease, MRD)
    • Profilo di farmacocinetica di venetoclax
    • Sicurezza
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - Subjects must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.
    - Adult male or female subjects > or = 18 years old.
    - Subjects should have laboratory values meeting the following criteria within the screening period prior to the first dose of study drug:
    • Absolute neutrophil count (ANC) > or = 1000/µL; subject may use growth factor support to achieve ANC eligibility criteria;
    • Platelets: > or = 50,000/mm3. For subjects with > 50% myeloma involvement in the marrow, a platelet count of > or = 30,000 mm3. Subjects may not have received a platelet transfusion within 72 hours prior to the platelet count used for eligibility;
    • Hemoglobin > or = 8.0 g/dL; subject may receive red blood cell (RBC) transfusions in accordance with institutional guidelines to meet this criteria;
    • AST and ALT < or = 3 × upper limit of normal (ULN);
    • Total bilirubin < or = 1.5 x ULN (subjects with documented Gilbert's syndrome, may have bilirubin > 1.5 × ULN);
    • Creatinine clearance > or = 30 mL/min, measured by 24-hour urine collection or calculated using the Cockcroft-Gault formula);
    • Serum calcium corrected for albumin < or = 14.0 mg/dL (< or = 3.5 mmol/L).
    - Subjects should be willing or able to comply with procedures required in this protocol.
    - Subjects should be willing and able to receive antithrombotic prophylactic treatment.
    - Documented diagnosis of multiple myeloma based on standard IMWG criteria.
    - Subject has an Eastern Cooperative Oncology Group (ECOG) performance status < or = 2.
    - Subject has documented disease progression on or within 60 days of completion of their last therapy.
    - Subject has received at least 2 prior lines of therapy.
    • A line of therapy consists of at least 1 complete cycle of a single agent, a regimen consisting of a combination of several drugs, or a planned sequential therapy of various regimens.
    - Subject must have received at least 2 consecutive cycles of lenalidomide and be relapsed/refractory to lenalidomide as defined by one of the following:
    • Subject experienced PD on or within 60 days of completing treatment.
    • Subject exhibited PR or better but relapsed within 6 months after stopping treatment.
    - Subject must have received at least 2 consecutive cycles of a proteasome inhibitor (bortezomib, carfilzomib or ixazomib).
    - Subject has measurable disease at Screening, defined by at least 1 of the following:
    • Serum M-protein > or = 0.5 g/dL (> or = 5 g/L); OR
    • Urine M-protein > or = 200 mg/24 hours; OR
    • Involved serum immunoglobulin free light chain (FLC) > or = 10 mg/dL (100 mg/L), provided serum FLC ratio is abnormal
    - Subject has MM positive for t(11;14) as determined by an analytically validated FISH assay per centralized laboratory testing.
    - A negative serum pregnancy test for all female subjects (except those of non-childbearing potential) within 10 to 14 days prior to initiating therapy and a negative urine pregnancy test within 24 hours for all female subjects (except those of non-childbearing potential) at baseline prior to the first dose of study drug.
    - If female, subject must be either postmenopausal, OR permanently surgically sterile OR for women of childbearing potential practicing at least 2 protocol-specified methods of birth control that are effective from at least 30 days before starting study drugs through at least 30 days after the last dose of any study drug.
    - If male, and subject is sexually active with female partner(s) of childbearing potential, he must agree, from Study Day 1 through 30 days after the last dose of study drug, to practice the protocol-specified contraception.
    - I soggetti devono volontariamente firmare e datare un consenso informato approvato dal Comitato Etico Indipendente, prima che possa essere eseguita qualsiasi procedura di screening o specifica per lo studio.
    - Soggetti adulti di ambo i sessi, di età > o = 18 anni.
    - I soggetti dovranno presentare valori di laboratorio in linea con i seguenti criteri durante il periodo di screening, prima della prima dose del medicinale sperimentale:
    • Conta assoluta dei neutrofili (ANC) > o = 1000/µL; è permesso il supporto con fattori di crescita per soddisfare il criterio di eleggibilità relativo all’ANC;
    • Piastrine: > o = 50.000/mm3. Nei soggetti con interessamento midollare del mieloma > 50%, livello di piastrine > o = 30.000 mm3. I soggetti non devono aver ricevuto una trasfusione di piastrine nelle 72 ore precedenti la misurazione dei livelli di piastrine utilizzata per determinare l’eleggibilità;
    • Emoglobina > o = 8,0 g/dL; il soggetto può ricevere trasfusioni di emazie (RBC) in accordo alle linee guida istituzionali al fine di soddisfare questo criterio;
    • AST e ALT < o = 3 volte il limite superiore della norma (ULN);
    • Bilirubina totale < o = 1,5 x ULN (nei soggetti con evidenza di sindrome di Gilbert, il valore di bilirubina può essere > 1.5 × ULN);
    • Clearance della creatinina > o = 30 mL/min, misurata su campione di urine delle 24 ore, oppure calcolata mediante formula Cockcroft-Gault;
    • Calcemia sierica corretta per valore di albumina < o = 14,0 mg/dL (< o = 3,5 mmol/L).
    - Soggetti in grado di e disponibili ad attenersi alle procedure previste da questo protocollo.
    - Soggetti in grado di e disponibili a ricevere profilassi antitrombotica.
    - Diagnosi documentata di mieloma multiplo in base ai criteri IMWG standard.
    - Soggetto con punteggio di stato funzionale ECOG (Eastern Cooperative Oncology Group) < o = 2.
    - Soggetto con progressione documentata di malattia in corso di trattamento oppure nei 60 giorni successivi alla conclusione dell’ultima terapia ricevuta.
    - Soggetto che ha ricevuto almeno 2 linee pregresse di terapia.
    • Una linea di terapia consiste di almeno un ciclo completo con agente singolo, un regime che consiste della combinazione di diversi farmaci oppure una terapia sequenziale pianificata di diversi regimi.
    - Il soggetto deve aver ricevuto almeno 2 cicli consecutivi di lenalidomide, ed essere recidivante/refrattario alla lenalidomide secondo quanto determinato in base a uno dei seguenti eventi:
    • Il soggetto ha presentato PD in corso di trattamento oppure nei 60 giorni successivi alla conclusione del trattamento
    • Il soggetto ha presentato una risposta uguale o migliore di PR ma ha avuto una recidiva nei 6 mesi successivi all’interruzione del trattamento.
    - Il soggetto deve aver ricevuto almeno 2 cicli consecutivi di un inibitore del proteasoma (bortezomib, carfilzomib o ixazomib).
    - Il soggetto deve avere malattia misurabile allo Screening, determinato in base ad almeno uno dei seguenti parametri:
    • Proteina M sierica > o = 0.5 g/dL (> o = 5 g/L); OPPURE
    • Proteina M urinaria > o = 200 mg/campione delle 24 ore ; OPPURE
    • L'immunoglobulina a catena leggera libera sierica coinvolta (free light chain, FLC) > o = 10 mg/dL (100 mg/L) purché il rapporto sierico delle FLC sia alterato
    - Soggetto con mieloma multiplo positivo per t(11;14) determinato in base a un dosaggio FISH validato analiticamente, mediante esame svolto dal laboratorio centralizzato.
    -Risultato negativo al test di gravidanza su siero per tutti i soggetti di sesso femminile (eccetto le donne non in età fertile) eseguito 10-14 giorni prima di iniziare la terapia, e risultato negativo al test di gravidanza su urine per tutti i soggetti di sesso femminile (eccetto le donne non in età fertile) eseguito al baseline nelle 24 ore precedenti la prima dose del medicinale sperimentale.
    - I soggetti di sesso femminile devono essere in menopausa, [....caratteri disponibili insufficienti. Si prega di far riferimento alla versione inglese]
    E.4Principal exclusion criteria
    Subject has history of treatment with venetoclax or another BCL-2 inhibitor or pomalidomide.
    Sub. has a history of other active malignancies, including myelodysplastic syndromes (MDS), within
    the past 3 years with the following exceptions:
    • Adequately treated in situ carcinoma of the cervix uteri or the breast;
    • Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;
    • Prostate cancer Gleason grade 6 or lower AND with stable Prostate Specific Antigen(PSA) levels off treatment; or
    • Previous malignancy with no current evidence of disease, and which was confined and surgically resected (or treated with other modalities) with curative intent and unlikely to impact survival during the duration of the study.
    Sub. has evidence of ongoing graft-versus-host disease (GvHD) if prior stem cell transplant (SCT).
    Sub. must not have received any live vaccines within 8 weeks prior to randomization
    Sub. has had prior treatment with the following:
    • Allogeneic or syngeneic SCT within 16 weeks prior to randomization; or
    • Autologous SCT within 12 weeks prior to randomization
    Sub. has known central nervous system involvement of multiple myeloma.
    Sub. has a history of clinically significant renal,neurologic,psychiatric,endocrinologic, metabolic,immunologic,cardiovascular,pulmonary or hepatic disease within the last 6 months that, in the opinion of the investigator, would adversely affect participation in this study.
    Subject has a history of known allergies, hypersensitivities, or intolerance to any of the study drug or
    excipients, or thalidomide derivatives.
    Sub. has the following conditions:
    • Nonsecretory multiple myeloma;
    • Active plasma cell leukemia i.e., either 20% of peripheral white blood cells or >2.0×109/L circulating plasma cells by standard differential;
    • Waldenström's macroglobulinemia;
    • Primary amyloidosis;
    • POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes);
    • Known human immunodeficiency virus (HIV) infection;
    • Active hepatitis B or C infection based on screening blood testing;
    • Significant cardiovascular disease, including uncontrolled angina, arrhythmia, recent myocardial infarction within 6 months prior to first dose, congestive heart failure NYHA Class >or=3;
    • Major surgery within 4 weeks prior to first dose or planned during study participation;
    • Acute infections within 14 days prior to first dose requiring parenteral therapy (antibiotic, antifungal, or antiviral);
    • Uncontrolled diabetes or hypertension within 14 days prior to first dose; or
    • Peripheral neuropathy >or= Grade 3 or >or= Grade 2 with pain within 2 weeks prior to first dose.
    Female who is pregnant, breastfeeding, or considering becoming pregnant during the study and for at least 30 days after the last dose of study drug.
    Male who is considering fathering a child or donating sperm during the study and for at least 30 days after the last dose of study drug.
    Sub. who have been treated with any systemic anti-myeloma therapies within 5 half-lives or 2 weeks prior to randomization, whichever is longer (or 2 weeks if half-life unknown), and through the last dose of any study drug
    Subject who have been treated with anti-myeloma radiotherapy within 2 weeks prior to randomization.
    Subject who have received corticosteroid therapy at a dose equivalent to >4mg daily of dexamethasone or a single dose of corticosteroid equivalent dose >40mg of dexamethasone within 2 weeks prior to randomization
    Sub. who have used systemic strong or moderate inhibitor or inducer of cytochromeP450(CYP)3A within 1 week prior to the first dose of study drugs
    Sub. who have used systemic strong inhibitor of CYP1A2 within 1 week prior to first dose.
    Sub. who have consumed grapefruit,grapefruit products,Seville oranges(including marmalade containing Seville oranges)or starfruit within 3 days prior to first dose.
    Sub. who anticipate the use of prohibited medications or foods during study participation
    Sub =Subject
    - Soggetto con storia di trattamento con venetoclax oppure con un altro inibitore del BCL-2 oppure con pomalidomide.
    - Soggetto con storia di altre neoplasie maligne attive, fra cui le sindromi mielodisplastiche (MDS), negli ultimi 3 anni, con le seguenti eccezioni:
    • Carcinoma della cervice uterina o della mammella in situ e trattato in maniera adeguata;
    • Carcinoma basocellulare cutaneo oppure carcinoma squamocellulare cutaneo localizzato;
    • Carcinoma della prostata di grado Gleason = 6 IN AGGIUNTA a valori stabili di PSA (Prostate Specific Antigen) senza trattamento; oppure
    • Neoplasia maligna pregressa senza alcuna evidenza attuale di malattia, che era circoscritta ed è stata asportata chirurgicamente (oppure trattata con altre modalità) con intento curativo, e che si associa a scarse probabilità di avere alcun impatto sulla sopravvivenza nel corso dello studio.
    - Soggetto con evidenza di malattia del trapianto verso l’ospite (graft-versus-host disease, GvHD) in atto, in caso di trapianto pregresso di cellule staminali (SCT).
    -Il soggetto non deve aver ricevuto alcun vaccino vivo nelle 8 settimane precedenti la randomizzazione
    - Soggetto che ha ricevuto uno dei seguenti trattamenti pregressi:
    • Trapianto allogenico o singenico di cellule staminali (SCT) nelle 16 settimane precedenti la randomizzazione; oppure
    • Trapianto autologo di cellule staminali nelle 12 settimane precedenti la randomizzazione
    - Soggetto con noto interessamento del sistema nervoso centrale del mieloma multiplo.
    - Soggetto con storia di patologia clinicamente significativa di natura renale, neurologica, psichiatrica, endocrinologica, metabolica, immunologica, cardiovascolare, polmonare oppure epatica negli ultimi 6 mesi che, a giudizio dello sperimentatore, avrebbe un effetto avverso sulla partecipazione a questo studio.
    - Soggetto con storia di note allergie, ipersensibilità o intolleranza a qualsiasi fra i medicinali sperimentali o agli eccipienti oppure ai derivati della talidomide.
    - Soggetto che presenta le seguenti condizioni:
    • Mieloma multiplo non secernente;
    • Leucemia plasmacellulare attiva, ovvero plasma cellule circolanti pari al 20% dei globuli bianchi nel sangue periferico oppure > 2,0 × 109/L in base a formula differenziale standard;
    • Macroglobulinemia di Waldenström;
    • Amiloidosi primaria;
    • Sindrome POEMS (polineuropatia, organomegalia, endocrinopatia, proteina monoclonale, e alterazioni cutanee)
    • Nota infezione da virus dell’immunodeficienza umana (HIV);
    • Infezione attiva da epatite B o C, in base agli esami ematochimici eseguiti allo screening;
    • Patologia cardiovascolare significativa, compresa angina non controllata, aritmia, infarto miocardico recente nei 6 mesi precedenti la prima dose, scompenso cardiaco congestizio di classe NYHA >o= 3;
    • Interventi chirurgici maggiori nelle 4 settimane precedenti la prima dose, oppure pianificati nel corso della partecipazione allo studio;
    • Infezioni acute nei 14 giorni precedenti la prima dose che richiedono terapia parenterale (antibiotica, anti-fungina oppure antivirale);
    • Diabete oppure ipertensione non controllata nei 14 giorni precedenti la prima dose; oppure
    • Neuropatia periferica di Grado > o = 3, oppure di Grado > o= 2 associato a dolore, nelle 2 settimane precedenti la prima dose.
    - Soggetto di sesso femminile in stato di gravidanza, che sta allattando, o che sta pianificando una gravidanza durante lo studio e per almeno 30 giorni dopo l’ultima dose del medicinale sperimentale.
    - Soggetto di sesso maschile che intende procreare o donare sperma nel corso dello studio, e per almeno 30 giorni dopo l’ultima dose del medicinale sperimentale.
    - Soggetto che ha ricevuto trattamento con qualsiasi terapia sistemica anti-mieloma entro un periodo corrispondente a 5 emivite oppure 2 settimane prima della randomizzazione, quale dei due periodi sia più lungo
    [....caratteri disponibili insufficienti. Si prega di far riferimento alla versione inglese]
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoint is progression-free survival (PFS) per Independent Review Committee (IRC) which is defined as the time in days from subject randomization to the date of the first documented progressive disease (PD) or death due to any cause, whichever occurs first.
    L'endpoint primario di efficacia è la sopravvivenza libera da progressione (PFS) determinato dal Comitato di revisione indipendente (IRC) che è definito dal tempo (espresso in giorni) trascorso dal momento della randomizzazione del soggetto fino alla data della prima progressione di malattia (PD) documentata oppure fino al decesso per qualsiasi causa, quale dei due eventi si manifesti per primo.
    E.5.1.1Timepoint(s) of evaluation of this end point

    PFS will be monitored throughout the study for PD or death whichever occurs first
    La PFS sarà monitorata durante lo studio per la PD o per la morte quale dei due si manifesti per primo.
    E.5.2Secondary end point(s)
    - Secondary Endpoints are:
    • Rate of very good partial response (VGPR) or better
    • Overall response rate (ORR)
    • Patient reported outcomes: Fatigue (PROMIS Fatigue Short Form 7a), Worst Pain (BPI-SF), Physical Functioning (EORTC QLQ-C30), and Global Heath Status/Quality of Life (EORTC QLQ-C30)
    • Overall survival (OS)
    • Duration of response (DOR)
    • Time to disease progression (TTP)
    • Time to response (TTR)
    • Minimal residual disease (MRD) negativity rate
    • Pharmacokinetics of venetoclax
    • Safety
    - Biomarker Samples will be collected to conduct exploratory investigations into known and/or novel biomarkers, including tumor BCL-2 family member expression, chromosomal abnormalities (gains, deletions, and/or mutations) and circulating markers of disease.
    - Safety evaluations include adverse event (AE) monitoring, physical examinations, vital sign measurements, electrocardiogram (ECG) variables, and clinical laboratory testing (hematology and chemistry)
    - Gli endpoint secondari sono:
    • Tasso di risposta parziale molto buona (VGPR) o migliore
    • Tasso di risposta generale (ORR)
    • Risultati riferiti dal paziente: affaticamento (forma abbreviata PROMIS Fatica 7a), Peggiore dolore (BPI-SF), funzionamento fisico (EORTC QLQ-C30) e globale Heath Status / Quality of Life (EORTC QLQ-C30)
    • Sopravvivenza globale (OS)
    • Durata della risposta (DOR)
    • Time to disease progression (TTP)
    • Tempo di risposta (TTR)
    • Tasso di negatività della malattia minima residua (MRD)
    • Farmacocinetica di venetoclax
    • Sicurezza
    - I campioni di biomarker saranno raccolti per condurre indagini esplorative su biomarcatori noti e / o nuovi, compresa l'espressione del membro della famiglia BCL-2 tumorale, anomalie cromosomiche (amplificazioni, delezioni e / o mutazioni) e marcatori circolanti della malattia malattia.
    -Le valutazioni di sicurezza includono il monitoraggio degli eventi avversi (AE), fisico esami, misurazioni dei segni vitali, elettrocardiogramma (ECG) variabili e test di laboratorio clinici (ematologia e chimica)
    E.5.2.1Timepoint(s) of evaluation of this end point
    - Biomarker Research will be collected at specified timepoints and monitored throughout the study.
    - PRO assessments will be collected at specified timepoints throughout the study.
    - Safety evaluations will be monitored for the entire study duration of the study.
    - PK samples for venetoclax will be evaluated for peak (i.e., 6 hour) and trough concentrations (Ctrough).
    - Efficacy endpoints will be evaluated throughout the study.
    - La ricerca sui biomarker sarà raccolta a orari specifici e monitorato durante lo studio.
    - Le valutazioni PRO saranno raccolte in determinati orari durante lo studio.
    - Le valutazioni di sicurezza saranno monitorate per l'intera durata dello studio.
    - I campioni di PK per venetoclax saranno valutati per il picco (cioè 6 ore) e concentrazioni minime (Ctrough).
    - Gli endpoint di efficacia saranno valutati durante lo studio.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA118
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Israel
    Japan
    Korea, Republic of
    Russian Federation
    Singapore
    Turkey
    Ukraine
    United States
    Denmark
    European Union
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end-of-study is defined as the last subject’s last visit, including survival.
    La fine dello studio è definita come ultima visita dell'ultimo soggetto, inclusa la sopravvivenza.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 134
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 110
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state15
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 120
    F.4.2.2In the whole clinical trial 244
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The full details of the treatment or care after participation can be found in the “M13-494 Treatment After End of Study” document included in the CTA. In summary, the provision of further treatment or care is at the discretion of the subject’s treating physician.
    I dettagli completi del trattamento o delle cure dopo la partecipazione possono essere trovati nel documento "M13-494 Trattamento dopo la fine dello studio" incluso nella CTA. In sintesi, la fornitura di ulteriori trattamenti o cure è a discrezione del medico curante del soggetto.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-07-06
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2018-06-21
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 17:51:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA